Management of extra-articular disease manifestations in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 16, Issue 3, 2004, Pages 206-211

  Turesson, Carl ^a,b   Matteson, Eric L ^a  

^a MAYO CLINIC   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Extra articular rheumatoid arthritis; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; ATORVASTATIN; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; ETANERCEPT; GLUCOCORTICOID; GOLD; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; LENERCEPT; METHOTREXATE; METHYLPREDNISOLONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ALLERGIC VASCULITIS; AMYLOIDOSIS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; EOSINOPHILIA; FELTY SYNDROME; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; KERATITIS; LEUKOCYTOCLASTIC VASCULITIS; LONG TERM CARE; LUNG DISEASE; LUNG FIBROSIS; MORTALITY; PATIENT MONITORING; PERICARDITIS; PLEURISY; POLYARTHRITIS; PREDICTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SCLERITIS; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME; VASCULITIS; CARDIOVASCULAR RISK; INFECTION RISK; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATIC DISEASE; RHEUMATOID VASCULITIS; TREATMENT RESPONSE;

ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HEMATOLOGIC DISEASES; HUMANS; INFECTION; LUNG DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1942467801     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200405000-00007     Document Type: Review

References (73)

1. Turesson C, O'Fallon WM, Crowson CS, et al.: Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002, 29:62-67.
2. Gordon DA, Stein JL, Broder I: The extra-articular features of rheumatoid arthritis: a systematic analysis of 127 cases. Am J Med 1973, 54:445-452.
3. Turesson C, Jacobsson L, Bergstrom U: Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 1999, 38:668-674.
4. Kremer JM, Alarcon GS, Weinblatt ME, et al.: Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997, 40:1829-1837.
5. Dawson JK, Graham DR, Desmond J, et al.: Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 2002, 41:262-267.
6. Alarcon GS, Kremer JM, Macaluso M, et al.: Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 1997, 127:356-364.
7. Scott DG, Bacon PA: Response to methotrexate in fibrosing alveolitis associated with connective tissue disease. Thorax 1980, 35:725-732.
8. Roschmann RA, Rothenberg RJ: Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy. Semin Arthritis Rheum 1987, 16:174-185.
9. Puttick MP, Klinkhoff AV, Chalmers A, et al.: Treatment of progressive rheumatoid interstitial lung disease with cyclosporine. J Rheumatol 1995, 22:2163-2165.
10. Chang HK, Park W, Ryu DS: Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. J Korean Med Sci 2002, 17:270-273.
11. Vassallo R, Matteson E, Thomas CF Jr: Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002, 122:1093-1096.
12. Gosset P, Perez T, Lassalle P, et al.: Increased TNF-alpha secretion by alveolar macrophages from patients with rheumatoid arthritis. Am Rev Respir Dis 1991, 143:593-597.
13. Russell ML, Gladman DD, Mintz S: Rheumatoid pleural effusion: lack of response to intrapleural corticosteroid. J Rheumatol 1986, 13:412-415.
14. Chapman PT, O'Donnell JL, Moller PW: Rheumatoid pleural effusion: response to intrapleural corticosteroid. J Rheumatol 1992, 19:478-480.
15. Escalante A, Kaufman RL, Quismorio FP Jr, et al.: Cardiac compression in rheumatoid pericarditis. Semin Arthritis Rheum 1990, 20:148-163.
16. Thould AK: Constrictive pericarditis in rheumatoid arthritis. Ann Rheum Dis 1986, 45:89-94.
17. Yurchak PM, Deshpande V: Case record of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 2-2003. A 60-year-old man with mild congestive heart failure of uncertain cause. N Engl J Med 2003, 348:243-249. Reviews the clinical and echocardiographic features of constrictive rheumatoid pericarditis.
18. Blake S: The clinical diagnosis of constrictive pericarditis. Am Heart J 1983, 106:432-433.
19. Felty AR: Chronic arthritis in the adult associated with splenomegaly and neutropenia. Bull Johns Hopkins Hosp 1924, 35:16-20.
20. Campion G, Maddison PJ, Goulding N, et al.: The Felty syndrome: a case-matched study of clinical manifestations and outcome, serologic features, and immunogenetic associations. Medicine (Baltimore) 1990, 69:69-80.
21. Sibley JT, Haga M, Visram DA, et al.: The clinical course of Felty's syndrome compared to matched controls. J Rheumatol 1991, 18:1163-1167.
22. Dillon AM, Luthra HS, Conn DL, et al.: Parenteral gold therapy in the Felty syndrome: experience with 20 patients. Medicine (Baltimore) 1986, 65:107-112.
23. Fiechtner JJ, Miller DR, Starkebaum G: Reversal of neutropenia with methotrexate treatment in patients with Felty's syndrome: correlation of response with neutrophil-reactive IgG. Arthritis Rheum 1989, 32:194-201.
24. Wassenberg S, Herborn G, Rau R: Methotrexate treatment in Felty's syndrome. Br J Rheumatol 1998, 37:908-911.
25. Talip F, Walker N, Khan W, et al.: Treatment of Felty's syndrome with leflunomide. J Rheumatol 2001, 28:868-870.
26. Joseph G, Neustadt DH, Hamm J, et al.: GM-CSF in the treatment of Felty syndrome. Am J Hematol 1991, 37:55-56.
27. Wagner DR, Combe C, Gresser U: GM-CSF and G-CSF in Felty's syndrome. Clin Invest 1993, 71:168-171.
28. Hazenberg BP, Van Leeuwen MA, Van Rijswijk MH, et al.: Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor: simultaneous induction of interteukin-6 release and flare-up of the arthritis. Blood 1989, 74:2769-2770.
29. Zakzook SI, Yunus MB, Mulconrey DS: Hyperviscosity syndrome in rheumatoid arthritis with Felty's syndrome: case report and review of the literature. Clin Rheumatol 2002, 21:82-85.
30. Papadaki HA, Kritikos HD, Valatas V, et al.: Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 2002, 100:474-482.
31. Chen KR, Toyohara A, Suzuki A, et al.: Clinical and histopathological spectrum of cutaneous vasculitis in rheumatoid arthritis. Br J Dermatol 2002, 147:905-913.
32. Scott DG, Bacon PA: Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 1984, 76:377-384.
33. Harper L, Cockwell P, Howie AJ, et al.: Focal segmental necrotizing glomerulonephritis in rheumatoid arthritis. Q J Med 1997, 90:125-132.
34. Guillevin L, Cohen P, Mahr A, et al.: Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003, 49:93-100. A well-conducted study of the use of cyclophosphamide in anti-neutrophil cytoplasmic antibody-associated vasculitis.
35. de Groot K, Adu D, Savage CO: The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001, 16:2018-2027.
36. Ahlmen M, Ahlmen J, Svalander C, et al.: Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin Rheumatol 1987, 6:27-38.
37. Foster CS, Forstot SL, Wilson LA: Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis: effects of systemic immunosuppression. Ophthalmology 1984, 91:1253-1263.
38. Vollertsen RS, Conn DL, Ballard DJ, et al.: Rheumatoid vasculitis: survival and associated risk factors. Medicine (Baltimore) 1986, 65:365-375.
39. Nicholls A, Snaith ML, Maini RN, et al.: Proceedings: Controlled trial of azathioprine in rheumatoid vasculitis. Ann Rheum Dis 1973, 32:589-591.
40. Heurkens AH, Westedt ML, Breedveld FC: Prednisone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med 1991, 151:2249-2254.
41. Upchurch KS, Heller K, Bress NM: Low-dose methotrexate therapy for cutaneous vasculitis of rheumatoid arthritis. J Am Acad Dermatol 1987, 17:355-359.
42. Doran MF, Crowson CS, Pond GR, et al.: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002, 46:2287-2293.
43. Doran MF, Crowson CS, Pond GR, et al.: Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002, 46:2294-2300.
44. Turesson C, Englund P, Jacobsson LT, et al.: Increased endothelial expression of HLA-DQ and interleukin 1 alpha in extra-articular rheumatoid arthritis: results from immunohistochemical studies of skeletal muscle. Rheumatology (Oxford) 2001, 40:1346-1354.
45. Maury CP, Liljestrom M, Laiho K, et al.: Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthritis Rheum 2003, 48:3068-3076. A retrospective study of pathogenetic factors, including TNF, in a large series of patients with RA and amyloidosis.
46. Lipsky PE, van der Heijde DM, St Clair EW, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-1602.
47. Bathon JM, Martin RW, Fleischmann RM, et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
48. Weinblatt ME, Keystone EC, Furst DE, et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35-45.
49. McCain ME, Quinet RJ, Davis WE: Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 2002, 41:116-117.
50. Jarrett SJ, Cunnane G, Conaghan PG, et al.: Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003, 30:2287-2291. This interesting and provocative case series features patients who experienced vasculitis during anti-TNF therapy, and discusses possible pathogenetic mechanisms.
51. Smith JS, Levinson RD, Holland GN, et al.: Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Care Res 2001, 45:252-257.
52. Kekow J, Welte T, Kellner U, Pap T: Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept. Arthritis Rheum 2002, 46:843-844.
53. McIlwain L, Carter JD, Bin-Sagheer S, et al.: Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol 2003, 36:411-413. Vasculitis during TNF inhibition in a patient with Crohn disease, indicating that such reactions are not limited to patients with RA.
54. Bartolucci P, Ramanoelina J, Cohen P, et al.: Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002, 41:1126-1132.
55. Unger L, Kayser M, Nusslein HG: Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis 2003, 62:587-588. Three patients with severe, refractory Ex-RA who responded to infliximab after treatment with cyclophosphamide was unsuccessful.
56. den Broeder AA, van den Hoogen FH, van de Putte LB: Isolated digital vasculitis in a patient with rheumatoid arthritis: good response to tumour necrosis factor alpha blocking treatment. Ann Rheum Dis 2001, 60:538-539.
57. Elkayam O, Hawkins PN, Lachmann H, et al.: Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002, 46:2571-2573.
58. Ciboddo G, Idone C: Treatment of renal amyloidosis in rheumatoid arthritis requires further investigation: comment on the case report by Elkayam et al. Arthritis Rheum 2003, 48:3299-3300.
59. Patatanian E, Thompson DF: A review of methotrexate-induced accelerated nodulosis. Pharmacotherapy 2002, 22:1157-1162.
60. Silman AJ, Newman J, MacGregor AJ: Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum 1996, 39:732-735.
61. Wolfe F: The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 2000, 27:630-637.
62. Turesson C, O'Fallon WM, Crowson CS, et al.: Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003, 62:722-727. In this paper on extra-articular manifestations in the Rochester RA cohort, smoking is identified as a major risk factor for extra-articular disease.
63. Goronzy JJ, Weyand CM: T-cell senescence and contraction of T-cell repertoire diversity: catalysts of autoimmunity and chronic inflammation. Arthritis Res 2003, 5:225-234. This excellent review provides a summary of the data on immunosenescence in RA and an analysis of its effect on pathogenesis, including that of vascular and extra-articular disease.
64. Scott DG, Bacon PA, Allen C, et al.: IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: comparative and serial studies during cytotoxic therapy. Clin Exp Immunol 1981, 43:54-63.
65. Mageed RA, Kirwan JR, Thompson PW, et al.: Characterisation of the size and composition of circulating immune complexes in patients with rheumatoid arthritis. Ann Rheum Dis 1991, 50:231-236.
66. Lorenz HM: T-cell-activation inhibitors in rheumatoid arthritis. BioDrugs 2003, 17:263-270. A review of available drugs and agents under development with an effect on T cells in RA.
67. Kremer JM, Westhovens R. Leon M, et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907-1915.
68. Silverman GJ, Weisman S: Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003, 48:1484-1492. Discusses the experience with anti-B cell therapy in various diseases, including RA.
69. Edwards JC, Cambridge G: Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001, 40:205-211.
70. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
71. Bellosta S, Bernini F, Ferri N, et al.: Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998, 137(Suppl):S101-S109.
72. Kwak B, Mulhaupt F, Veillard N, et al.: The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 2001, 131:41-46.
73. McCarey DW, Sattar N, Hampson R, et al.: A randomized, placebo controlled trial comparing the anti-inflammatory and vascular risk modulatory effects of atorvastatin in rheumatoid arthritis. Arthritis Rheum 2003, 48:3667. The first randomized, controlled trial on statin treatment in RA reveals a marked effect on C-reactive protein levels.